Published in Am J Pathol on February 01, 2002
Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci (2004) 1.30
Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem (2002) 1.13
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol (2011) 0.94
Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age (Dordr) (2011) 0.92
Proteolytically inactive insulin-degrading enzyme inhibits amyloid formation yielding non-neurotoxic aβ peptide aggregates. PLoS One (2013) 0.87
Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery. Am J Pathol (2002) 0.76
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol (1961) 45.34
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 6.09
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A (1999) 5.75
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A (1997) 5.66
Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science (1982) 5.63
Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 5.42
An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science (1994) 5.10
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem (1975) 4.29
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci (1999) 3.85
Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA (1999) 3.22
Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 3.18
Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol (1998) 2.85
Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain (1976) 2.76
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J Neurosci (2001) 2.12
Necropsy evidence of central cholinergic deficits in senile dementia. Lancet (1977) 1.97
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol (2001) 1.87
Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging (2000) 1.83
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem (1998) 1.68
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol (1984) 1.60
In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol (1996) 1.45
Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc Natl Acad Sci U S A (1996) 1.45
Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J Neurosci (1996) 1.36
Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res (1999) 1.34
Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci (2000) 1.32
Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem (1996) 1.31
Hippocampal neuron and synaptophysin-positive bouton number in aging C57BL/6 mice. Neurobiol Aging (1999) 1.30
Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol (1998) 1.29
Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res (1983) 1.29
Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol (2000) 1.28
Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci (1999) 1.25
Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol (1999) 1.25
Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci (1982) 1.21
beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol (2001) 1.17
Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett (1982) 1.14
Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol (1999) 1.12
Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci (1999) 1.11
Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem (1998) 1.08
Aging increased amyloid peptide and caused amyloid plaques in brain of old APP/V717I transgenic mice by a different mechanism than mutant presenilin1. J Neurosci (2000) 1.04
Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study. Ann Neurol (2000) 1.02
Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest (1994) 1.01
Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci U S A (1999) 1.00
The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol (1998) 1.00
Age-related alterations in the rodent brain cholinergic system and behavior. Neurobiol Aging (1980) 1.00
The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase. J Biol Chem (2000) 0.99
[18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse (1998) 0.98
Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol (1998) 0.97
The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol (2000) 0.96
Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res (2000) 0.94
Regulation of amyloid precursor protein cleavage. J Neurochem (1999) 0.94
Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging (1997) 0.92
Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis (2000) 0.91
Convergent cholinergic activities in aging and Alzheimer's disease. Neurobiol Aging (1992) 0.89
Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience (1994) 0.87
Alzheimer's disease in man and transgenic mice: females at higher risk. Am J Pathol (2001) 0.86
Mouse brain distribution of a carbon-11 labeled vesamicol derivative: presynaptic marker of cholinergic neurons. Life Sci (1990) 0.86
Effects of age and sex on the water maze performance and hippocampal cholinergic fibers in rats. Neurosci Lett (1999) 0.85
Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183). Proc Natl Acad Sci U S A (1987) 0.85
Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J Med Chem (1996) 0.84
Presynaptic markers of cholinergic function in the rat brain: relationship with age and cognitive status. Neuroscience (1999) 0.83
Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis (2001) 0.81
Long-term neuropathological and neurochemical effects of nucleus basalis lesions in the rat. Science (1987) 0.80
High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Ann N Y Acad Sci (1996) 0.80
Identification of sodium-dependent, high-affinity choline uptake sites in rat brain with [3H]hemicholinium-3. J Neurochem (1986) 0.78
Topochemical localization of choline acetyltransferase and acetylcholinesterase in mouse brain. Brain Res (1984) 0.76
Neurotransmitter enzymes in telencephalon, brain stem and cerebellum during the entire life span of the mouse. Mech Ageing Dev (1980) 0.76
Regional concentrations of choline and acetylcholine in the rat brain. J Neurochem (1974) 0.76
Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology (2013) 3.56
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol (2006) 2.93
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction. J Neurosci (2005) 2.55
Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain (2010) 2.37
ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci (2009) 2.31
Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab (2006) 2.16
TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol (2006) 1.88
Initial agonist treatment of Parkinson disease: a critique. Neurology (2003) 1.82
β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord (2012) 1.69
Early menopausal hormone use influences brain regions used for visual working memory. Menopause (2010) 1.67
Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology (2014) 1.59
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole. Exp Neurol (2003) 1.53
Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab (2013) 1.49
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) (2006) 1.48
Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology (2002) 1.45
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann Neurol (2006) 1.41
Procedure guideline for brain death scintigraphy. J Nucl Med (2003) 1.41
The relationship between alcohol use and risk-taking sexual behaviors in a large behavioral study. Prev Med (2004) 1.37
Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab (2012) 1.32
Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int (2003) 1.32
Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. Int J Radiat Biol (2009) 1.29
SNM practice guideline for brain death scintigraphy 2.0. J Nucl Med Technol (2012) 1.28
11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med (2005) 1.24
Interlaboratory comparison of the dicentric chromosome assay for radiation biodosimetry in mass casualty events. Radiat Res (2008) 1.23
Protein synthesis in the amygdala, but not the auditory thalamus, is required for consolidation of Pavlovian fear conditioning in rats. Eur J Neurosci (2003) 1.21
A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Stat Med (2004) 1.18
Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol Aging (2010) 1.16
Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol (2012) 1.14
Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology (2005) 1.13
Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem (2002) 1.13
Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain (2013) 1.12
Nonfatal Suicidal Behaviors in U.S. Army Administrative Records, 2004-2009: Results from the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS). Psychiatry (2015) 1.11
Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. Radiat Res (2010) 1.07
Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med (2011) 1.06
Brain PET in suspected dementia: patterns of altered FDG metabolism. Radiographics (2014) 1.05
Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factor. Int J Radiat Biol (2010) 1.05
Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology (2012) 1.04
In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J Nucl Med (2014) 1.04
Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab (2007) 1.02
Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain (2011) 1.02
Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr (2010) 1.01
Synergistic effects of Munc18a and X11 proteins on amyloid precursor protein metabolism. J Biol Chem (2002) 1.01
Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf (2012) 0.99
Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. AJR Am J Roentgenol (2008) 0.99
Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry (2005) 0.98
Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain (2011) 0.98
Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp Neurol (2012) 0.98
Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol (2010) 0.97
ApoE receptor 2 regulates synapse and dendritic spine formation. PLoS One (2011) 0.96
Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord (2013) 0.96
Positron emission tomography imaging of (2R,3R)-5-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. Nucl Med Biol (2009) 0.95
Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res (2006) 0.95
Tocopherol succinate: a promising radiation countermeasure. Int Immunopharmacol (2009) 0.94
HYOU1/Orp150 expression in breast cancer. Med Sci Monit (2007) 0.93
Utility of SPECT/CT with Meckel's scintigraphy. Ann Nucl Med (2009) 0.93
Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis. Nat Commun (2011) 0.93
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. J Neurochem (2004) 0.92
Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RAD(R) in mice. J Radiat Res (2012) 0.92
Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol (2002) 0.92
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Implicating calpain in tau-mediated toxicity in vivo. PLoS One (2011) 0.91
Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Res (2011) 0.91
Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR Am J Roentgenol (2010) 0.90
Tocopherol succinate: modulation of antioxidant enzymes and oncogene expression, and hematopoietic recovery. Int J Radiat Oncol Biol Phys (2010) 0.90
Preclinical development of a bridging therapy for radiation casualties. Exp Hematol (2010) 0.90
Semiquantification and classification of local pulmonary function by V/Q single photon emission computed tomography in patients with non-small cell lung cancer: potential indication for radiotherapy planning. J Thorac Oncol (2011) 0.90
Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia. Ann Neurol (2003) 0.90
Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol (2006) 0.89
Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch Gen Psychiatry (2007) 0.89
In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol (2009) 0.89
Changes in global function and regional ventilation and perfusion on SPECT during the course of radiotherapy in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 0.89
The combined effect of age and basal follicle-stimulating hormone on the cost of a live birth at assisted reproductive technology. Fertil Steril (2007) 0.89
Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. Mov Disord (2014) 0.89
The cytoplasmic adaptor protein X11alpha and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement. FASEB J (2009) 0.88
5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis. J Radiat Res (2012) 0.88
Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement (2008) 0.88
X11alpha haploinsufficiency enhances Abeta amyloid deposition in Alzheimer's disease transgenic mice. Neurobiol Dis (2009) 0.87
Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol (2007) 0.87
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol (2005) 0.87
FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer (2010) 0.87
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. ACS Chem Neurosci (2014) 0.86
Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. J Nucl Med (2013) 0.86
Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol (2009) 0.86
A tetra(ethylene glycol) derivative of benzothiazole aniline enhances Ras-mediated spinogenesis. J Neurosci (2013) 0.85
ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. J Neurochem (2002) 0.85
Health-related behaviors in young military smokers. Mil Med (2004) 0.85
Validation of consensus panel diagnosis in dementia. Arch Neurol (2010) 0.85
Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology. J Geriatr Psychiatry Neurol (2002) 0.85
Clinical markers for identifying cholinergic deficits in Parkinson's disease. Mov Disord (2014) 0.84
Uses of proton pump inhibitors and serum potassium levels. Pharmacoepidemiol Drug Saf (2009) 0.84
Postmenopausal hormone use impact on emotion processing circuitry. Behav Brain Res (2011) 0.84
Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med (2013) 0.84